Wedoany.com Report-Oct. 2, GSK, a global biopharmaceutical company, has unveiled plans to invest $30 billion over the next five years in the United States to advance research and development (R&D) and enhance supply chain infrastructure. This investment strengthens GSK’s existing innovation and manufacturing presence in the U.S., focusing on developing and producing medicines for the domestic market.

A key component of this plan includes a $1.2 billion investment in advanced manufacturing and technology. This encompasses the construction of a new biologics flex factory in Upper Merion, Pennsylvania, set to begin in 2026, aimed at producing advanced medicines for respiratory conditions like COPD and asthma, as well as cancers, including hematological, gynecological, lung, and other solid tumors. The investment also covers the integration of AI and advanced digital technologies across GSK’s five manufacturing sites in Pennsylvania, North Carolina, Maryland, and Montana, alongside new drug substance manufacturing and enhanced device and auto-injector assembly capabilities.

Emma Walmsley, CEO of GSK, stated: “Alongside the many longstanding and vital shared interests that connect the U.K. and the United States, is advancing life sciences to get ahead of disease. The State Visit brings together two countries that have led the world in science and healthcare innovation. We are proud to be part of both. Here in the U.K., we continue to invest in a significant manufacturing base and more than 1.5 billion pounds in R&D every year. Today, we are committing to invest at least 30 billion dollars in the United States over the next 5 years, further bolstering the already strong R&D and supply chain we have in the country. 1.2 billion dollars of the announcement includes construction of an additional next-gen biologics ‘flex’ factory, powered by AI, advanced technologies and expert talent to produce transformational new respiratory and cancer medicines for American patients.”

The $30 billion investment includes significant funding for R&D, drug discovery, and clinical trials, with the U.S. expected to lead globally in the number of GSK’s studies, sites, and trial participants over the next five years. Additionally, GSK has committed approximately $2 billion to U.S. manufacturing in the past year, including an $800 million facility in Marietta, Pennsylvania, where construction began in October 2024, doubling the site’s capacity. These initiatives are expected to create hundreds of skilled jobs, adding to GSK’s U.S. workforce of about 15,000.

This strategic investment reinforces GSK’s commitment to advancing healthcare innovation, enhancing supply chain resilience, and supporting economic growth through job creation in the U.S., while delivering cutting-edge treatments for patients.